AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01006252
Drug: Tasisulam-sodium
RxNorm normalized name: Tasisulam
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously on Day 1 of a 28-day cycle, until disease progression.
Trial: NCT01006252
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/m\^2 administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
Trial: NCT00032175
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00285662
Drug: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children will get 25mg/1.25mg/kg of SP as a single dose, 4 mg/kg for 3 days of Artesunate and 10 mg/kg for 3 days of Amodiaquine in their respective arms
Trial: NCT04519905
Drug: Paclitaxel plus carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Paclitaxel （45mg/m2) plus carboplatin (AUC=2); five cycles; qw
Trial: NCT02535975
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets metformin 500 mg PO three times a day for 24 weeks
Trial: NCT03480932
Drug: Sofosbuvir
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Direct acting antiviral agent used for the treatment of hepatitis C
Trial: NCT03480932
Drug: Daclatasvir
RxNorm normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Direct acting antiviral agent used for the treatment of hepatitis C
Trial: NCT03480932
Drug: Pegylated Interferon alfa-2a
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiviral agent used for the treatment of hepatitis C
Trial: NCT00953771
Drug: Danazol
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol 600 mg PO will be initiated with plasma exchange and corticosteroids at the time of enrollment.
Trial: NCT03435601
Drug: Anifrolumab
RxNorm normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV Administration of Anifrolumab 300 mg every 4 weeks from week 0 to week 20 for a total of 6 doses.~At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period).
Trial: NCT01235130
Drug: OMEGA-3
RxNorm normalized name: Omega-3
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg, 2 caps, twice a day
Trial: NCT01235130
Drug: Placebo soybean oil
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg, 2caps twice a day
Trial: NCT00003253
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00943345
Drug: indometacin
RxNorm normalized name: Indometacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * capsule for oral consumption~* at 22h00 evening before test day: 75 mg~* at 7h30 on the test day: 50 mg This intervention will be applied 4 times (4 arms).
Trial: NCT03344211
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01969682
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
Trial: NCT00127205
Drug: clodronate disodium
RxNorm normalized name: clodronate disodium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01607879
Drug: Standard of care ADT + (HMB + arginine + glutamine)
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 packet of HMB+arginine+glutamine contains 1.5 g of the amino acid metabolite HMB + 7 g arginine and 7 g glutamine.~Take one packet twice daily for 3 months
Trial: NCT00474721
Drug: acetaminophen with codeine
RxNorm normalized name: acetaminophen with codeine ORAL ELIXIR
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01778062
Drug: Indacaterol
RxNorm normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indacaterol 150µg once daily oral inhalation
Trial: NCT01778062
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo once daily oral inhalation
Trial: NCT02088957
Drug: Brivaracetam intravenous solution
RxNorm normalized name: brivaracetam Oral Solution
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Solution for infusion~* Concentration: 10 mg/mL~* Route of Administration: Intravenous bolus use
Trial: NCT02088957
Drug: Brivaracetam oral tablets
RxNorm normalized name: brivaracetam Oral Tablet
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 10 mg and 25 mg tablets; Daily Dose: 200 mg/day (100 mg bid)~* Route of Administration: Oral use
Trial: NCT00702962
Drug: Vorinostat, Carboplatin, Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Study originally a Phase I standard dose escalation of the study medication Vorinostat with sequential cohorts of 3-6 participants entered to 3 dose levels (200mg, 300mg, 400mg). Dose escalation stopped after participant 1 on dose level 2 due to recently published research identifying an appropriate dosing regimen. A set dose was then to be administered to all subsequent participants. This regimen (a cycle) consisted of Vorinostat on Day 1 through Day 4, Carboplatin AUC 6 on Day 3, and Etoposide 100 mg/m2 on Day 3 through Day 5. Treatment cycles were repeated every 21 days (3 weeks) for 4 cycles total.
Trial: NCT03031496
Drug: GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets)
RxNorm normalized name: hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets) are cream-colored, circular, flat faced uncoated tablets with beveled edges having break line on one side and BD embossed on the other side.
Trial: NCT03031496
Drug: Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets)
RxNorm normalized name: amiloride hydrochloride / hydrochlorothiazide Oral Tablet [Moduretic]
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets) tablets are peach-colored, half scored, diamond shaped tablets marked MSD917.
Trial: NCT00895557
Drug: chantix
RxNorm normalized name: Chantix
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: .5 mg once a day 1 to 3, .5 mg twice a day on days 4 to 7, 1 mg from day 8 to end of treatment
Trial: NCT01941004
Drug: fingolimod
RxNorm normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
Trial: NCT01941004
Drug: Placebo (6mos) + open label fingolimod (6 mos)
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
Trial: NCT01054196
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: daily dose dependent on dose-escalation schedule
Trial: NCT01054196
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/m2 given Days -2 and -1
Trial: NCT03796013
Drug: Entrectinib Form A
RxNorm normalized name: entrectinib
DrugBank: Entrectinib (DB11986)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive a single oral dose of entrectinib form A under fasted conditions.
Trial: NCT03796013
Drug: Entrectinib Form C
RxNorm normalized name: entrectinib
DrugBank: Entrectinib (DB11986)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive a single oral dose of entrectinib form C under fasted conditions.
Trial: NCT00655330
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan (160mg/day)
Trial: NCT00655330
Drug: Probucol
RxNorm normalized name: Probucol
DrugBank: Probucol (DB01599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probucol (750mg/day)
Trial: NCT02133924
Drug: natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Natalizumab 300mg on days 0 and 14.
Trial: NCT01728805
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00322075
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00241046
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01533818
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80-100 mg/kg/day in 2 divided doses for 7 days~For convenience dose divided into six weight bands Table 2: Dose of amoxicillin Weight band Amount per dose Daily dose Lower Limit (mg or units /kg/d) Upper Limit (mg or units /kg/d) Amoxicillin - desired range 75-100 mg/kg/day (25mg/ml (125mg/5ml); twice daily orally)\* 1.8-1.9 kg 3.0 ml 150 mg 75.4 100.0 2.0-2.4 kg 4.0 ml 200 mg 80.3 100.0 2.5-2.9 kg 5.0 ml 250 mg 83.6 100.0 3.0-3.9 kg 6.0 ml 300 mg 75.2 100.0 4.0-4.9 kg 8.0 ml 400 mg 80.2 100.0 5.0-5.9 kg 10.0 ml 500 mg 83.5 100.0
Trial: NCT01533818
Drug: Sugar Syrup
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be given 2 times/day for 7 days
Trial: NCT02574845
Drug: Metformin HCl
RxNorm normalized name: metformin HCl
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02574845
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02277184
Drug: Ficlatuzumab
RxNorm normalized name: Ficlatuzumab
DrugBank: Ficlatuzumab (DB11680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2C - 8C)
Trial: NCT02277184
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each vial contains 10 mg of DDP, 19 mg of sodium chloride, 100 mg of mannitol, and hydrochloric acid for pH adjustment. One vial is reconstituted with 10 ml of sterile water. The pH range will be 3.5 to 4.5.~Cisplatin will be given as a bolus, infused over 1-2 hours along with appropriate hydration and anti-emetics.~Reconstituted solution of cisplatin is stable for 20 hours when stored at 27°C and should be protected from light if not used within 6 hours. The vials and injection should not be refrigerated. Cisplatin has been shown to react with aluminum needles, producing a black precipitate within 30 minutes.
Trial: NCT01956604
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00350038
Drug: Irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00350038
Drug: Ciprofibrate
RxNorm normalized name: ciprofibrate
DrugBank: Ciprofibrate (DB09064)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05431218
Drug: Cholecalciferol Liquid
RxNorm normalized name: cholecalciferol Oral Liquid Product
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily single dose of the drug in the first half of the day in an individually selected dose for 3 months
Trial: NCT02812940
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: GvHD prophylaxis
Trial: NCT01853475
Drug: PQP tablets 960mg
RxNorm normalized name: pegvaliase-pqpz
DrugBank: Pegvaliase (DB12839)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Piperaquine phosphate tablets 960mg
Trial: NCT01853475
Drug: PQP tablets 1440mg
RxNorm normalized name: pegvaliase-pqpz
DrugBank: Pegvaliase (DB12839)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Piperaquine phosphate tablets 1440mg
Trial: NCT01853475
Drug: OZ439+TPGS 800mg
RxNorm normalized name: TPGS
DrugBank: Tocofersolan (DB11635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OZ439+TPGS prototype formulation 800mg
Trial: NCT01853475
Drug: OZ439 PIB 800mg
RxNorm normalized name: C-11 PiB
DrugBank: Pittsburgh Compound B (DB15161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OZ439 Powder in Bottle Aqueous Solution 800mg
Trial: NCT01093677
Drug: LIM-0705
RxNorm normalized name: Landiololumhttps://lims.drugbank.com/drugs/DB12212/edit#
DrugBank: Landiolol (DB12212)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Oral solution 750 mg LIM 0705 BID for 14 days.
Trial: NCT01695122
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01630343
Drug: Paracetamol tablet and Tramadol capsule
RxNorm normalized name: tramadol and paracetamol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Panadol 500mg tablet Q4H prn Tramadol 50mg capsule Q4H prn
Trial: NCT01630343
Drug: Panadol 500mg tablet, tramadol 50mg capsule
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Regular Panadol 500mg tds with tramadol 50mg capsule tds for 3 weeks after injury
Trial: NCT04039503
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC as add-on to the pre-trial background medication.
Trial: NCT01097460
Drug: MM-111 + Herceptin
RxNorm normalized name: Herceptin
DrugBank: MM-111 (DB17983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV
Trial: NCT01298687
Drug: Travoprost Ophthalmic Solution, 0.00013%
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cumulative daily dose is below the travoprost ophthalmic solution, 0.004% once daily dose
Trial: NCT01298687
Drug: Travoprost Ophthalmic Solution, 0.00033%
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cumulative daily dose equals the travoprost ophthalmic solution, 0.004% once daily dose
Trial: NCT01298687
Drug: Travoprost Ophthalmic Solution, 0.001%
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
Trial: NCT01298687
Drug: Travoprost Ophthalmic Solution, 0.00267%
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
Trial: NCT01298687
Drug: Travoprost Ophthalmic Solution, 0.004%
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01298687
Drug: Travoprost Vehicle
RxNorm normalized name: Travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inactive ingredients used as an active comparator
Trial: NCT00310557
Drug: Gadopentetate dimeglumine (Magnevist)
DrugBank: Gadopentetic acid (DB00789)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Approximately 0.1mmol/kg body weight, single intravenous administration on the study day
Trial: NCT03596762
Drug: Elinzanetant (BAY3427080)
RxNorm normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY3427080 capsules
Trial: NCT01213173
Drug: Succinate Metoprolol (Betaloc ZOK®)
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment with 47.5mg for two weeks, if tolerated and without Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3, the dosage will be titrated to 95mg and last for another 6 weeks
Trial: NCT01213173
Drug: Succinate Metoprolol (Betaloc ZOK®)
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with 95mg for two weeks, and if tolerated and without bradycardia symptoms presented, Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3，the dosage will be force titrated to 190mg and last for another 6 weeks
Trial: NCT00643292
Drug: amoxicillin/clavulanate postassium (Augmentin ES-600)
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amoxicillin/clavulanate postassium 90/6.4 mg/kg/day, given in divided doses q12h, for 10 days
Trial: NCT00227942
Drug: Estrogen Replacement Therapy
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17-b-Estradiol Patch, .05 mg/day; applied for 7 days
Trial: NCT00227942
Drug: Zolpidem
RxNorm normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/day, po qhs
Trial: NCT00214019
Drug: salmeterol
RxNorm normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: salmeterol diskus 50 mcg twice per day
Trial: NCT00214019
Drug: Fluticasone
RxNorm normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo diskus, fluticasone MDI 88 mcg twice per day
Trial: NCT01179152
Drug: Budesonide turbuhaler, Budesonide+Formoterol turbuhaler
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 200 mcg turbuhaler or Budesonide+Formoterol 160mcg turbuhaler
Trial: NCT01346072
Drug: tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral, 30 mg, single dose, one time administration
Trial: NCT00669877
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 IV days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses.
Trial: NCT00669877
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses)
Trial: NCT00669877
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses)
Trial: NCT00669877
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mcg/kg
Trial: NCT00669877
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg intrathecal day 7 +/- 2 days (odd courses); 3 gm/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
Trial: NCT01492153
Drug: biphasic human insulin
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
Trial: NCT00286806
Drug: AT-101
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03017235
Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Supplied as two sachets per subject. Subjects will be instructed to reconstitute the medication by combining the contents of one packet with approximately five (5) ounces of cold water and stirring for two to three minutes.
Trial: NCT02043730
Drug: Nab-paclitaxel and Gemcitabine
RxNorm normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy will consist of nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
Trial: NCT02043730
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.